211 Mt. Airy Road
Tel: (908) 992-6400
About Daiichi Sankyo
Daiichi Sankyo Group is dedicated to the creation and supply of innovative pharmaceutical therapies to improve standards of care and address diversified, unmet medical needs of people globally by leveraging our world-class science and technology.
With more than 100 years of scientific expertise and a presence in more than 20 countries, Daiichi Sankyo and its 15,000 employees around the world draw upon a rich legacy of innovation and a robust pipeline of promising new medicines to help people. In addition to a strong portfolio of medicines for cardiovascular diseases, under the Group’s 2025 Vision to become a “Global Pharma Innovator with Competitive Advantage in Oncology,” Daiichi Sankyo is primarily focused on providing novel therapies in oncology, as well as other research areas centered around rare diseases and immune disorders. For more information, please visit: www.daiichisankyo.com.
For more information, please visit: www.daiichisankyo.com. Daiichi Sankyo, Inc., headquartered in Basking Ridge, New Jersey, is a member of the Daiichi Sankyo Group. To learn more about Daiichi Sankyo, Inc., please visit www.dsi.com.
STOCK EXCHANGE: Tokyo Stock Exchange
STOCK SYMBOL: 4568
365 articles with Daiichi Sankyo
Daiichi Sankyo Advances Leadership in Oncology with Potentially Practice Changing Data at 2021 ESMO Congress
Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) will present new research data across its antibody drug conjugate (ADC) portfolio in a broad range of cancers at the 2021 European Society for Medical Oncology (#ESMO21) Virtual Congress to be held September 16 to 21, 2021.
9/7/2021Is your job burning you out? According to BioSpace's recent research, approximately 70% of biotech professionals feel burned out. Is it time to look for a new job? The good news is that biotech companies keep adding jobs and the market is hot! Check out these hot companies that are looking for c...
8/16/2021There was plenty of clinical trial updates last week. Here’s a look.
ImmVira announces MVR-C5252 targeting Glioblastoma has received the U.S. FDA clearance to proceed with clinical trial on August 6, 2021.
ENHERTU® Significantly Improved Progression-Free Survival in DESTINY-Breast03 Head-to-Head Trial Versus Trastuzumab Emtansine (T-DM1) in Patients with HER2 Positive Metastatic Breast Cancer
Positive topline results from the head-to-head DESTINY-Breast03 phase 3 trial showed that ENHERTU®, the Daiichi Sankyo Company, Limited and AstraZeneca HER2 directed antibody drug conjugate, demonstrated superiority over trastuzumab emtansine.
The clinical study compared Enhertu to Kadcyla in HER2+ metastatic breast cancer patients who previously received trastuzumab.
Novartis claimed the patents held by Plexxikon were invalid. Unfortunately for the company, the jury found it was unable to prove these claims.
BioSpace’s Pharm Country Hotbed ranges from Connecticut, New York, New Jersey, Pennsylvania and Rhode Island.
DESTINY-Breast09 Head-to-Head First-Line Phase 3 Trial of ENHERTU® Initiated in Patients with HER2 Positive Metastatic Breast Cancer
DESTINY-Breast09 Head-to-Head First-Line Phase 3 Trial of ENHERTU ® Initiated in Patients with HER2 Positive Metastatic Breast Cancer.
Daiichi Sankyo Advances Science Across Three Lead DXd ADCs with New Data in Multiple Cancers at 2021 ASCO Virtual Meeting
Data to highlight promising early efficacy of patritumab deruxtecan in patients with TKI-resistant, EGFR-mutated locally advanced or metastatic non-small cell lung cancer
4/29/2021Biopharma and life sciences companies from across the globe provide updates on their businesses and pipelines.
Guardant Health Announces Collaboration With Daiichi Sankyo to Develop Guardant360® CDx as a Companion Diagnostic for Enhertu® in Advanced Metastatic Non-Small Cell Lung Cancer
Guardant Health, Inc. (Nasdaq: GH) today announced a strategic collaboration with Daiichi Sankyo, Inc. (Daiichi Sankyo) to pursue regulatory approval and commercialization of the Guardant360® CDx blood test as a companion diagnostic for Enhertu® (fam-trastuzumab deruxtecan-nxki)
DESTINY-CRC02 Phase 2 Trial of ENHERTU® Initiated in Patients with HER2 Overexpressing Advanced Colorectal Cancer
DESTINY-CRC02 Phase 2 Trial of ENHERTU ® Initiated in Patients with HER2 Overexpressing Advanced Colorectal Cancer
Pennsylvania Biotechnology Center (PABC) announces new collaboration and $10 million investment pledge from Daiichi Sankyo, Inc.
The nonprofit Pennsylvania Biotechnology Center, one of the nation’s most successful life sciences incubators, announced a new collaboration that includes a pledge by Daiichi Sankyo to become an investor in the fund managed by Hatch Biofund Management LLC.
Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) today announced Ken Takeshita, MD will be named the new Global Head of Research & Development as of April 1, 2021.
New Survey Reveals Nearly Half of Women Are Unfamiliar with a Condition that Affects Up to Five Million Adults in the U.S.¹
The Get Iron Informed survey sheds light on knowledge of Iron Deficiency Anemia (IDA) - a condition that impacts one in five women of childbearing age
Daiichi Sankyo Company, Limited announced that ENHERTU®, a HER2 directed antibody drug conjugate, received the Prime Minister’s Award at the 9th Technology Management and Innovation Awards hosted by the Japan Techno-Economics Society.
Daiichi Sankyo’s and AstraZeneca’s Enhertu (fam-trastuzumab deruxtecan-nxki) has become the first HER2-directed medication approved to treat gastric cancer in the U.S. in 10 years.
New Research Data Across DXd ADC Portfolio at WCLC Showcases Daiichi Sankyo’s Continued Commitment in Lung Cancer
Interim DESTINY-Lung01 research data from the HER2 overexpressing metastatic non-small cell lung cancer (NSCLC) cohort of ENHERTU ® will be featured as late-breaker presentation Updated TROPION-PanTumor01 results of datopotamab deruxtecan in patients with advanced NSCLC to be highlighted Biomarker analysis from phase 1 trial of patritumab deruxtecan in patients with previously treated metastatic or locally advanced EGFR
A phase 3 study from Daiichi Sankyo Company conducted in Japan, South Korea and Taiwan found that mirogabalin, an orally administered gabapentinoid, was associated with a significantly greater improvement in pain among patients with central neuropathic pain after spinal cord injury compared with ...